Navigation Links
New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
Date:12/21/2007

PRINCETON, N.J., Dec. 21 /PRNewswire/ -- Otsuka Pharmaceutical Development & Commercialization, Inc. announced today that the U.S. Food and Drug Administration has accepted a new drug application (NDA) for the company's investigational oral once-daily medication tolvaptan, a selective V2-vasopressin receptor antagonist, for two indications: treatment of adults with worsening heart failure and treatment of hyponatremia.(1) These indications are based on data from three phase 3 pivotal trials.(2)

OPDC was established in 2007 by Otsuka America, Inc. (OAI). OPDC is wholly owned by OAI, which is the holding company for Otsuka Pharmaceutical Co., Ltd. (OPC) interests in the U.S. OAI is wholly owned by OPC.

Tolvaptan is a novel, investigational small molecule designed to be an antagonist of the vasopressin V2 receptor, which plays a role in the kidney's regulation of fluid excretion. The majority of patients hospitalized for worsening heart failure have edema or excess body fluid, which is treated with diuretics to excrete the fluid. In contrast to diuretics, tolvaptan is designed to promote aquaresis, the excretion of electrolyte-free water. In clinical trials, the most common adverse reactions in patients with worsening heart failure (incidence greater than or equal to 5% in patients treated with tolvaptan and double the incidence of patients treated with placebo) were thirst, dry mouth and polyuria. In patients with hyponatremia, the most common adverse reactions in clinical trials (incidence greater than or equal to 5% in patients treated with tolvaptan and double the incidence of patients treated with placebo) were thirst, dry mouth, asthenia, constipation, pollakiuria and hyperglycemia. The most serious adverse events were cardiogenic shock (1.7% in patients receiving tolvaptan vs. 1.2% of patients receiving placebo), pulmonary embolism (1.3% in patients receiving tolvaptan vs. 0.8% for patients receiving placebo,) and gout (4.7% in patients rece
'/>"/>

SOURCE Otsuka Pharmaceutical Development & Commercialization,Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
3. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
4. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
5. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
8. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
11. Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... City, Utah (PRWEB) August 27, 2014 ... that will expand its current Salt Lake City manufacturing ... underway outside of Utah to ultimately create 1,000 new ... 20 years. , “Utah is home to hardworking ... whom can be credited with Varian’s success in the ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Global Biodegradable Packaging ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable Packaging ... readily decomposed by the action of microorganisms. ... in terms of raw materials, production technology, ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new ... Global Chelating Agents Market 2014-2018 ... Chelating Agent A chelating agent is a chemical ... ions, thereby forming a metal-ion complex. It reduces ... chemical processes, formulations, and the environment by chelating ...
(Date:8/27/2014)... August 27, 2014 “We are honored ... vendors,” said Ven Thangaraj, CEO of Radiant Sage. “We ... are taking the imaging corelab market to a different ... and research organizations to efficiently and effectively manage the ... data to be analyzed and read by trained physicians. ...
Breaking Biology Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2
... Third Wave Technologies Inc. has announced that the southwestern ... Wave's Invader Hepatitis C Virus genotyping reagents. , ,The reagents ... of the Hepatitis C virus, a blood-transmitted disease estimated to ... percent of those infected do not know it, according to ...
... Mountain States Health Alliance , a regional health care ... the Milwaukee-based Johnson Controls, Inc. , for system-wide ... System will be installed throughout the health care system, ... for a variety of voice and data services. , ...
... CHICAGO So you snagged a job offer from one of ... This is a big step. Think of it as getting an ... the gratification we all feel when we are wanted (not to ... unemployed) can at times overwhelm our good judgment. , ,Taking a ...
Cached Biology Technology:Tennessee health care system to install Johnson Controls wireless tech 2Ten red flags in your Midwest technology offer letter 2Ten red flags in your Midwest technology offer letter 3Ten red flags in your Midwest technology offer letter 4Ten red flags in your Midwest technology offer letter 5
(Date:8/28/2014)... northern California, and Alaska totaled 515 million board feet ... increase of more than 10 percent compared to the ... Northwest Research Station reported today. During this same period, ... 247 million board feet. , The total value of ... to $390 million in the same quarter, while the ...
(Date:8/28/2014)... Ludwig-Maximilians-Universitaet (LMU) in Munich have assigned a number ... predatory arthropods. These animals lived in shallow marine ... forms found in Jurassic strata. , Before ... marine habitat and were fossilized some 435 million ... of the Silurian seas although they were ...
(Date:8/27/2014)... mechanical force that a single fungal cell or bacterial colony ... it plays a heavy role in setting up some of ... may not be too much of a stretch to say ... ability to respond to the touch of beneficial fungi, according ... of agronomy at the University of Wisconsin-Madison. , "Many ...
Breaking Biology News(10 mins):West coast log exports up, lumber exports down in second quarter of 2014 2Paleontology: Oldest representative of a weird arthropod group 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3
... by scientists at The University of Texas Medical School ... vascular smooth-muscle cells in people who suffer from hereditary ... warning in the prime of their lives. Thoracic ... dissections, is the 15th leading cause of death in ...
... appealed for more information on the worlds biodiversity to ... to understand the impact of climate change on the ... by the Biotechnology and Biological Sciences Research Council (BBSRC), ... and computer scientists at the University of Cardiff, has ...
... Researchers at Childrens Hospital of Pittsburgh of UPMC are participating ... effectiveness of oral insulin in preventing or delaying the onset ... disease. The researchers want to determine if one insulin ... type 1 diabetes in relatives of people who are found ...
Cached Biology News:Life-threatening gene defect located by UT-Houston researchers 2Life-threatening gene defect located by UT-Houston researchers 3Life-threatening gene defect located by UT-Houston researchers 4How global is the Global Biodiversity Information Facility? 2Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes 2
... every research laboratory, the revolutionary Luminex 100 ... inexpensively and in real time enhancing your ... system includes the Luminex 100, the XY ... technology which enables you to simultaneously assay ...
... source of amino acids and peptides ... casein. It is recommended for laboratory ... used in antibiotics, toxins and enzyme ... microbiology pH6.8 0.5 at 25 C, ...
... Human Hep G2 cells were cultured in ... and harvested at the log phase of growth. ... their native forms, cells were fixed in acetone-methanol. ... (5 mm) adhesive coated slide, with each wells ...
... cultured in Minimum Essential Medium (Eagle) with 2 ... of growth. In order to keep the ... in acetone-methanol. The cells are arrayed on ... each wells surface specifically treated to enhance cellular ...
Biology Products: